Terlipressin as a therapy of Hepatorenal Syndrome - what is the statement of Plasmatic expression and hemodynamic Motoring

被引：1

作者：

Umgelter, Andreas ^{[1
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin 2, D-81675 Munich, Germany

来源：

ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2009年 / 47卷 / 03期

关键词：

D O I：

10.1055/s-0028-1109113

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：307 / 308

页数：2

共 40 条

[31] Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome
Abdel-Razik, Ahmed
Mousa, Nasser
Abdelsalam, Mostafa
Abdelwahab, Ahmed
Tawfik, Mona
Tawfik, Ahmed M.
Hasan, Ahmad S.
Elhelaly, Rania
El-Wakeel, Niveen
Eldars, Waleed
FRONTIERS IN PHARMACOLOGY, 2020, 11
[32] INCREASED BASELINE INDICATORS OF INFLAMMATION IN PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 AND GRADE 3 ACUTE-ON-CHRONIC LIVER FAILURE: IMPLICATIONS FOR TERLIPRESSIN THERAPY
Wong, Florence
Pappas, S. Chris
Vargas, Hugo E.
Jamil, Khurram
HEPATOLOGY, 2023, 78 : S1340 - S1341
[33] Comparison of Survival Rates and Morbidity With Norepinephrine Plus Albumin Versus Terlipressin Plus Albumin Therapy in Treating Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
Moole, Harsha
Shah, Anushi
Boddireddy, Raghuveer R.
Moole, Vishnu
Uppu, Achuta
GASTROENTEROLOGY, 2016, 150 (04) : S1085 - S1085
[34] PREDICTORS OF RESPONSE TO THERAPY WITH TERLIPRESSIN AND ALBUMIN IN PATIENTS WITH CIRRHOSIS AND HEPATORENAL SYNDROME - ACUTE KIDNEY INJURY (HRS-AKI) ACCORDING TO NEW INTERNATIONAL CLUB OF ASCITES (ICA) CRITERIA
Agrawal, Jatin
Kumar, Ashish
Arora, Anil
Sharma, Praveen
Singla, Vikas
Bansal, Naresh
Anikhindi, Shrihari
GUT, 2020, 69 : A13 - A13
[35] TERLIPRESSIN, IN COMBINATION WITH ALBUMIN, MAY IMPROVE RENAL FUNCTION AND DECREASE THE NEED FOR RENAL REPLACEMENT THERAPY IN PATIENTS AGED ≥65 YEARS WITH ACUTE KIDNEY INJURY FROM HEPATORENAL SYNDROME
Pyrsopoulos, Nikolaos T.
Sclair, Seth N.
Gallegos-Orozco, Juan F.
Jamil, Khurram
GASTROENTEROLOGY, 2022, 162 (07) : S1115 - S1115
[36] Terlipressin Treatment of Patients With Hepatorenal Syndrome Type 1 Decreased the Need for Renal Replacement Therapy in Transplant Recipients: A 12-Month Follow-Up of the CONFIRM Study
Jamil, Khurram
Weinberg, Ethan
Reddy, Rajender
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S853 - S853
[37] PRETRANSPLANT TERLIPRESSIN TREATMENT FOR HEPATORENAL SYNDROME DECREASES THE NEED FOR RENAL REPLACEMENT THERAPY BOTH PRE- AND POSTTRANSPLANT: A 12-MONTH FOLLOW-UP ANALYSIS OF THE CONFIRM TRIAL
Weinberg, Ethan M.
Wong, Florence
Vargas, Hugo E.
Curry, Michael P.
Jamil, Khurram
Pappas, S. Chris
Reddy, K. Rajender
HEPATOLOGY, 2022, 76 : S145 - S146
[38] PARTIAL RESPONSE TO TERLIPRESSIN THERAPY, AS PER INTERNATIONAL CLUB OF ASCITES (ICA) CRITERIA, IS ASSOCIATED WITH A LOWER END-OF-TREATMENT ACUTE-ON- -CHRONIC LIVER FAILURE GRADE AND FEWER ORGAN FAILURES IN PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 (HRS)
Wong, Florence
Pappas, S. Chris
Curry, Michael P.
Pyrsopoulos, Nikolaos
Jamil, Khurram
HEPATOLOGY, 2022, 76 : S1209 - S1210
[39] Sequential CLIF-SOFA (C-S) scores decrease with terlipressin therapy and correlate more strongly with survival than baseline scores, in subjects with acute-on-chronic-liver failure (ACLF) and hepatorenal syndrome Type 1 (HRS-1)
Wong, Florence
Pappas, Stephen Chris
Sanyal, Arun J.
Jamil, Khurram
HEPATOLOGY, 2017, 66 : 960A - 961A
[40] Time for a new, more inclusive endpoint for treatment of type 1 hepatorenal syndrome (HRS-1)? Small changes in serum creatinine (SCr) of >20% are equivalent to HRS reversal (HRSR) in predicting survival and need for renal replacement therapy (RRT) during treatment of HRS-1 with terlipressin and albumin.
Boyer, Thomas D.
Wong, Florence
Sanyal, Arun J.
Pappas, Stephen Chris
Jamil, Khurram
HEPATOLOGY, 2016, 64 : 1030A - 1031A

← 1 2 3 4 →